Latest Product Development News

Appen Limited reported a 9.2% revenue decline to $103.2 million for H1 2025, offset by robust 67% growth in its China business unit. Despite increased net losses, the company maintains a strong cash position and focuses on generative AI expansion and operational efficiency.

Xref Limited reported a significantly reduced net loss for FY2025 and a return to positive EBITDA, driven by strategic cost restructuring and a transition to a SaaS business model.

Generation Development Group (GDG) delivered a robust FY25 performance, marked by strategic acquisitions and a surge in funds under management, positioning itself as a dominant force in Australia's wealth management sector.

Aquirian Limited reported a 13% revenue increase to $26.1 million in FY25, securing a $20 million three-year contract with a Western Australian goldmine and advancing its innovative Collar Keeper® technology.

ImpediMed Limited has posted a 23% increase in revenue for the 2025 financial year, yet its net loss widened by 17%, with no dividends declared. The company’s financials, audited by Ernst & Young, reveal a complex picture of growth paired with escalating costs.

Ai-Media Technologies reported a 2.1% revenue decline to $64.86 million in FY25, driven by a strategic shift to technology sales and a 25% drop in services revenue. Despite a higher net loss, underlying EBITDA rose 11%, reflecting progress in its SaaS transformation and global expansion.

Sprintex Limited reported a 26% revenue increase for FY25 but also a 37% rise in net loss, as it accelerates global expansion through key distribution deals and manufacturing upgrades.

Shriro Holdings reported a 5.5% rise in EBITDA for FY25 despite a 13.6% revenue dip, driven by strategic shifts including a new US distributor and innovative BBQ product launches.

Shriro Holdings reported a 13.6% revenue decline to $103.3 million in FY25 but delivered a 5.5% rise in EBITDA and an 8.7% increase in net profit after tax. The company completed a $15 million share buy-back and deferred its final dividend as it explores alternative capital uses.

Nutritional Growth Solutions has settled to exit non-core US agreements, unlocking nearly $580,000 in financial relief and streamlining its strategic focus.

Optiscan Imaging Limited has launched a $17.75 million fully underwritten entitlement offer to fund clinical trials, regulatory approvals, and product development. Peters Investments underwrites the offer, potentially increasing its stake to nearly 39%.

Optiscan Imaging Ltd has launched a fully underwritten $17.75 million entitlement offer to fund clinical trials and regulatory clearances for its medical devices, marking a pivotal step in its transition to a commercial medical device manufacturer.